ZYDUS LIFESCIENCES LIMITED
Geojit BNP Paribas
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
16 Apr 2025 | Zydus Lifesciences |
Geojit BNP Paribas
|
908.60 | 975.00 | 822.10 (10.52%) | 7.31 |
Buy
|
||||
16 Apr 2025 | Commodities |
IDBI Capital
|
Sector Update
|
||||||||
16 Apr 2025 | HG Infra Engineering |
Axis Direct
|
1137.90 | 1201.00 | 1117.80 (1.80%) | Target met |
Buy
|
||||
16 Apr 2025 | World Economy and Markets |
Axis Direct
|
Daily Note
|
Daily Fundamental View:16 April 2025
Axis Direct
Asian markets are trading lower, mirroring the US markets as investors evaluate quarterly earnings amid ongoing concerns over tariffs that continue to dampen sentiment. Nikkei, Hang Seng, and Shanghai are trading lower by 0.63%, 1.71%, and 0.54%, respectively.
|
|||||||
16 Apr 2025 | InterGlobe Aviation |
Axis Direct
|
5521.00 | 5800.00 | 5244.50 (5.27%) | 5.05 |
Buy
|
||||
16 Apr 2025 | ICICI Prudential |
BOB Capital Markets Ltd.
|
642.20 | 674.00 | 586.30 (9.53%) | 4.95 |
Buy
|
||||
15 Apr 2025 | Fino Payments Bank |
Ventura
|
246.77 | 291.00 | 249.02 (-0.90%) | 17.92 |
Buy
|
||||
15 Apr 2025 | ICICI Prudential |
Sharekhan
|
642.20 | 750.00 | 567.15 (13.23%) | 16.79 |
Buy
|
VNB margins beat estimates, growth muted
Sharekhan
APE declined 3% y-o-y in Q4FY25, while VNB grew by 2% y-o-y. For FY25, APE grew 15% y-o-y, Individual APE grew by 13% and value of new business (VNB) grew by 6% y-o-y. VNB margins improved to 22.7% (up 120 bps y-o-y/ up 150 bps q-o-q) versus estimates of 21.9% in Q4 driven by product mix changed towards non-par segment and retail protection.
|
|||
15 Apr 2025 | ABB |
Motilal Oswal
|
5961.00 | 6700.00 | 5246.50 (13.62%) | 12.40 |
Buy
|
Remains focused on new areas
Motilal Oswal
ABB, in its annual report, highlighted its focus on high-growth segments and deeper penetration into Tier 2 cities, along with new product development. During the year, the company continued to benefit from demand for premium products and increased penetration into Tier 2 and Tier 3 cities.
|
|||
15 Apr 2025 | ICICI Lombard |
Motilal Oswal
|
1895.10 | 2200.00 | 1822.60 (3.98%) | 16.09 |
Buy
|
Beat on combined ratio; PAT miss due to investment income
Motilal Oswal
ICICIGI’s gross written premium was 10% up YoY in 4QFY25 to INR69b (in line), impacted by 1/n regulation implementation for long-term products. NEP grew 20% YoY to INR52.3b (15% beat). For FY25, it grew 17% YoY to INR198b.
|
|||
more
loading
|